Charles Holmsten, MD
Adult Medicine · Rosenberg, TXNPI 1083728711
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $667 of the $747 with a category attached, or 89.3%. It is spread thinly across 15 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $256 and has fallen 65.6% since, to $88 in 2025.
Across 38 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$162
- Novo Nordisk$97
- Astellas Pharma US Inc$95
- AstraZeneca$95
- Lilly USA, LLC$65
- Pfizer$60
- plus $173 from 9 others
What the payments were for
- Food & beverage$66789%
- Education$8011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 8 | $162 |
| Novo Nordisk | 5 | $97 |
| Astellas Pharma US Inc | 2 | $95 |
| AstraZeneca | 6 | $95 |
| Lilly USA, LLC | 4 | $65 |
| Pfizer | 3 | $60 |
| Exact Sciences | 2 | $47 |
| GSK | 1 | $22 |
| AbbVie | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Gilead | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Optinose US, Inc. | 1 | $13 |
| Novartis | 1 | $12 |
How this compares
$747 in reported general payments places this provider in the 55th percentile of 98 adult medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 64 | $70,037 |
| GlyxambiEmpagliflozin/Linagliptin | 42 | $40,245 |
| OzempicSemaglutide | 21 | $36,043 |
| EliquisApixaban | 41 | $27,600 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 33 | $24,318 |
| JanuviaSitagliptin Phosphate | 16 | $18,338 |
| XareltoRivaroxaban | 17 | $15,161 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $14,131 |
| FarxigaDapagliflozin Propanediol | 16 | $11,373 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $9,061 |
| Novolin NInsulin Nph Human Isophane | 12 | $3,320 |
| Novolog FlexpenInsulin Aspart | 12 | $2,886 |
| Levothyroxine Sodium | 158 | $1,530 |
| Amlodipine Besylate | 251 | $1,343 |
| Gabapentin | 97 | $1,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $97 | $36,04321 claims |
| PfizerEliquis | $60 | $27,60041 claims |
| Johnson & JohnsonXarelto | $13 | $15,16117 claims |
| AstraZenecaFarxiga | $95 | $11,37316 claims |
| GSKTrelegy Ellipta | $22 | $9,06114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 98 adult medicine providers in Texas.
Other adult medicine in Rosenberg
- Deborah HornBellaire$723K
- Thomas MartensPflugerville$87K
- Sakuntalai SrinanthakumarBeaumont$48K
- Francisco Vera AdamesSpring$11K
- Latisha RoweHouston$11K
- Hong XiaoCarrollton$10K
- Mark NovasSheppard Afb$9K
- Daisy ArceWeslaco$9K
- Jeffory ThomasTexarkana$8K
- Manuel SanchezMcAllen$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.